SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Goldman Sachs Downgrades Phathom Pharmaceuticals to Sell, Announces $34 Price Target

Goldman Sachs analyst Paul Choi downgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Neutral to Sell and announces $34 price target.

Benzinga · -
Goldman Sachs analyst Paul Choi downgrades Phathom Pharmaceuticals (NASDAQ: PHAT) from Neutral to Sell and announces $34 price target.